Feverfew - An Ancient Remedy for Modern Times?

Berry M.I. Feverfew faces the future. Pharmaceutical J 1984; 232: 611–4

Johnson S. Feverfew. A traditional herbal remedy for migraine and arthritis. London: Sheldon Press, 1984

Editorial. Feverfew - A new drug or an old wives’ remedy? Lancet 1985; i: 1084

Hancock K. Feverfew. Your headache may be over. New Canaan, Connecticut: Keats Publishing, 1986

Britt J. , Keen L. Miracle Plants. Feverfew. A guide to its history, uses and miraculous properties. London: Century Hutchinson, 1987

Johnson E.S. , Kadam N.P. , Hylands D.M. , Hylands P.J. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985; 291: 569–73

Johnson E.S. Mims magazine 1983; May 15: p 32

Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc 1763; 195: Chap. 33

Collier H.O.J. , Butt N.M. , McDonald-Gibson W.J. , Saeed S.A. Extracts of feverfew inhibit prostaglandin synthesis. Lancet 1980; ii: 922

Makheja A.N. , Bailey J.M. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes and Med 1982; 8: 653–60

Heptinstall S. , White A. , Williamson L. , Mitchell J.R.A. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985, i: 1071–4

Capasao F. The effect of an aqueous extract of Tanacetum parthenium L. on arachidonic acid metabolism by rat peritoneal leucocytes. J Pharm Pharmacol 1986; 38: 71–2

Keery R.J. , Lumley P. Does feverfew extract exhibit phospholipase A₂ inhibitory activity in vivo? Br J Pharmacol 1986; 89: 834P

Loesche W. , Michel E. , Heptinstall S. An extract of feverfew inhibits the behaviour of human polymorphonuclear leucocytes. (Submitted for publication)

Hayes N.A. , Foreman J.C. The activity of compounds extracted from feverfew on histamine release from rat mast celss. J Pharm Pharmacol 1987; 39: 466–70

O'Neill L.A.J. , Barrett M.L. , Lewis G.P. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononu-nuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 1987; 23: 81–3

Groenewegen W.A. , Knight D.W. , Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an α-methylene butyrolactone unit. J Pharm Pharmacol 1986; 38: 709–12

Heptinstall S. , Groenewegen W.A. , Spangenberg P. , Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J Pharm Pharmacol 1987; 39: 459–65

Heptinstall S. , Groenewegen W.A. , Knight D.W. , Spangenberg P. , Loesche W. Studies on feverfew and its mode of action. In: Rose F. Clifford ed. Current problems in neurology: 4. Advances in headache research. Proceedings of the 6th International Migraine Symposium. London: John Libbey, 1987: 129–34.

Baldwin C.A. , Anderson L.A. , Phillipson J.D. What pharmacists should know about feverfew. Pharmaceutical J 1987; 239: 237–8

Groenewegen W.A. , Heptinstall S. Amounts of feverfew in commercial preparations of the herb. Lancet 1986; i: 44–5

Johnson E.S. , Kadam N.P. , Anderson D. Investigation of possible genetoxic effects of feverfew in migraine patients. Human Toxicol 1987; 6: 533–4